Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 8/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18503369 | 0.92 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3HTR1ACHRNB2 | |
| SCHEMBL13499926 | 0.92 | PTGDR2 (0.42) | SLC6A2SLC6A4SLC6A3HTR1ACHRNB2 | |
| SCHEMBL14864497 | 0.90 | PTGDR2 (0.44) | SLC6A2SLC6A4SLC6A3HTR1ACHRNB2 | |
| SCHEMBL24632926 | 0.88 | OPRL1 (0.40) | SLC6A2SLC6A4SLC6A3HTR1ACHRNB2 | |
| SCHEMBL19621290 | 0.88 | OPRL1 (0.42) | SLC6A2SLC6A4SLC6A3HTR1ACHRNB2 | |
| SCHEMBL12917728 | 0.88 | PDE2A (0.37) | SLC6A2SLC6A4SLC6A3HTR1ACHRNB2 | |
| SCHEMBL18503370 | 0.88 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3HTR1ACHRNB2 | |
| SCHEMBL19088439 | 0.87 | OPRL1 (0.45) | SLC6A2SLC6A4SLC6A3HTR1ACHRNB2 | |
| SCHEMBL10266582 | 0.87 | SLC6A2 (0.58) | SLC6A2SLC6A4SLC6A3HTR1ACHRNB2 | |
| SCHEMBL30915 | 0.86 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3HTR1ACHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024019957-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CELGENE CORPORATION (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20230234925-A1 | GPR52 MODULATORS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234925-A1 | GPR52 MODULATORS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-07-27 | — | — | US | disclosed |
| WO-2022198196-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022140555-A1 | CARBOXYLIC ACID CONTAINING INDANYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CELGENE CORPORATION (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2021216705-A1 | GPR52 MODULATORS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-10-28 | — | — | WO | disclosed |
| WO-2017155844-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
| US-9758492-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-12 | — | — | US | disclosed |
| US-20170253609-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2017-09-07 | — | — | US | disclosed |
| EP-3039020-B1 | IDO INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-07-19 | — | — | EP | disclosed |
| US-20160200674-A1 | IDO INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-07-14 | — | — | US | disclosed |
| EP-2900645-A1 | 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION | Bayer CropScience AG (DE) | 2015-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200674-A1 | IDO INHIBITORS | IDO1, IDO2, INMT | SLC6A2 2639/4885SLC6A4 1687/4885SLC6A3 2326/4885 |
| US-20230234925-A1 | GPR52 MODULATORS AND METHODS OF USE | GPR52, GPR68, GPR35 | SLC6A2 366/4885SLC6A4 608/4885SLC6A3 739/4885 |
| US-20170253609-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, PYGL, SLC10A1 | SLC6A2 4460/4885SLC6A4 4614/4885SLC6A3 4587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.